McKusick-Nathans Institute of the Department of Genetic Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Genome Med. 2021 Aug 11;13(1):129. doi: 10.1186/s13073-021-00944-5.
Tumor response to therapy is affected by both the cell types and the cell states present in the tumor microenvironment. This is true for many cancer treatments, including immune checkpoint inhibitors (ICIs). While it is well-established that ICIs promote T cell activation, their broader impact on other intratumoral immune cells is unclear; this information is needed to identify new mechanisms of action and improve ICI efficacy. Many preclinical studies have begun using single-cell analysis to delineate therapeutic responses in individual immune cell types within tumors. One major limitation to this approach is that therapeutic mechanisms identified in preclinical models have failed to fully translate to human disease, restraining efforts to improve ICI efficacy in translational research.
We previously developed a computational transfer learning approach called projectR to identify shared biology between independent high-throughput single-cell RNA-sequencing (scRNA-seq) datasets. In the present study, we test this algorithm's ability to identify conserved and clinically relevant transcriptional changes in complex tumor scRNA-seq data and expand its application to the comparison of scRNA-seq datasets with additional data types such as bulk RNA-seq and mass cytometry.
We found a conserved signature of NK cell activation in anti-CTLA-4 responsive mouse and human tumors. In human metastatic melanoma, we found that the NK cell activation signature associates with longer overall survival and is predictive of anti-CTLA-4 (ipilimumab) response. Additional molecular approaches to confirm the computational findings demonstrated that human NK cells express CTLA-4 and bind anti-CTLA-4 antibodies independent of the antibody binding receptor (FcR) and that similar to T cells, CTLA-4 expression by NK cells is modified by cytokine-mediated and target cell-mediated NK cell activation.
These data demonstrate a novel application of our transfer learning approach, which was able to identify cell state transitions conserved in preclinical models and human tumors. This approach can be adapted to explore many questions in cancer therapeutics, enhance translational research, and enable better understanding and treatment of disease.
肿瘤对治疗的反应既受肿瘤微环境中存在的细胞类型的影响,也受细胞状态的影响。这对于许多癌症治疗方法都是如此,包括免疫检查点抑制剂(ICI)。虽然已经确定 ICI 可促进 T 细胞激活,但它们对肿瘤内其他免疫细胞的更广泛影响尚不清楚;需要这些信息来确定新的作用机制并提高 ICI 的疗效。许多临床前研究已经开始使用单细胞分析来描绘肿瘤内个别免疫细胞类型的治疗反应。这种方法的一个主要限制是,临床前模型中确定的治疗机制未能完全转化为人类疾病,从而限制了在转化研究中提高 ICI 疗效的努力。
我们之前开发了一种称为 projectR 的计算转移学习方法,用于识别独立的高通量单细胞 RNA 测序(scRNA-seq)数据集之间的共享生物学。在本研究中,我们测试了该算法识别复杂肿瘤 scRNA-seq 数据中保守和临床相关转录变化的能力,并将其应用扩展到 scRNA-seq 数据集与其他数据类型(批量 RNA-seq 和质谱流式细胞术)的比较。
我们在抗 CTLA-4 反应性的小鼠和人类肿瘤中发现了 NK 细胞激活的保守特征。在人类转移性黑色素瘤中,我们发现 NK 细胞激活特征与更长的总生存期相关,并且可以预测抗 CTLA-4(ipilimumab)反应。其他分子方法证实了计算发现,表明人类 NK 细胞表达 CTLA-4 并独立于抗体结合受体(FcR)结合抗 CTLA-4 抗体,并且与 T 细胞类似,NK 细胞的 CTLA-4 表达受细胞因子介导和靶细胞介导的 NK 细胞激活修饰。
这些数据表明我们的转移学习方法的一种新应用,该方法能够识别在临床前模型和人类肿瘤中保守的细胞状态转变。这种方法可以适用于探索癌症治疗中的许多问题,增强转化研究,并更好地理解和治疗疾病。